Please use this identifier to cite or link to this item:
Tetteh, Ebenezer K.
Morris, Stephen
Year of Publication: 
[Journal:] Health Economics Review [ISSN:] 2191-1991 [Volume:] 4 [Year:] 2014 [Issue:] 26 [Pages:] 1-16
Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses or health technology assessments to determine which medical technologies offer value-for-money. The manner in which these assessments are conducted suggests that, holding all else equal, the economic value of biologic drugs may be determined by how much is spent on administering these drugs or trade-offs between drug acquisition and administration costs. Yet, on the supply-side, it seems very little attention is given to how manufacturing and formulation choices affect healthcare delivery costs. This paper evaluates variations in the administration costs of biologic drugs, taking care to ensure consistent inclusion of all relevant cost resources. From this, it develops a regression-based algorithm with which manufacturers could possibly predict, during process development, how their manufacturing and formulation choices may impact on the healthcare delivery costs of their products.
Administration costs
Economic evaluation
Persistent Identifier of the first edition: 
Creative Commons License:
Document Type: 

Files in This Item:
792.57 kB

Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.